OVX-033

Phase 1 study to evaluate safety and immunogenicity of sarbecovirus (coronavirus) vaccine candidate, OVX033, at ascending dose levels The trial will enroll 48 participants in France LYON, France--(BUSINESS WIRE)-- Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial (NCT06128382) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate. Recently, preclinical data published in Frontiers in Immunology demonstrated OVX033’s proof of cross-protection against three SARS-CoV-2 variants of concern. In a rabbit toxicology study, the vaccine candidate also showed an excellent safety and tolerance pro intramuscular administration. The first-in-human study will be conducted at the Clinical Investigation Center in Vaccinology Cochin Pasteur (CIC) in Cochin Hospital in Paris (AP-HP, Inserm) under the supervision of Odile Launay, MD, PhD, Professor at Paris Cité University. “OVX033 has been shown in preclinical models to effectively provide broad protection across multiple strains of coronavirus,” commented Prof. Odile Launay, the Principal Investigator. “We are proud to participate in this first-in-human study to evaluate the vaccine candidate’s role in preventing the pandemic-level spread of current and future SARS-CoV-2 variants.” “Transitioning our second broad-spectrum vaccine candidate into the clinic further validates our self-assembling nanoparticle platform, OligoDOMTM, and our position as a pioneer in the advancement of a new class of vaccines,” said Alexandre Le Vert, CEO & Co-Founder of Osivax. “With the Phase 1 initiation for OVX033 underway, we hope to advance a broad-spectrum coronavirus vaccine that can be positioned against all SARS-CoV-2 variants and against future coronavirus pandemic threats.” The single-center trial is a randomized, double-blind, placebo-controlled Phase 1 clinical study evaluating the safety and immunogenicity of OVX033 at three dose levels (100 µg, 250 µg, and 500 µg). One single dose of OVX033 vaccine or of placebo will be administered intramuscularly in 48 healthy subjects aged 18-49 years. OVX033 is based on Osivax’ cutting-edge technology, OligoDOMTM, which has already established promising proof-of-concept data with OVX836, a broad-spectrum influenza A vaccine candidate currently being evaluated in several Phase 2 clinical studies. Results on immunogenicity, safety and preliminary efficacy were published in The Lancet Infectious Disease in 2023. About OVX033 OVX033 is a first-in-class coronavirus vaccine candidate that targets the nucleocapsid (N), a highly conserved internal antigen. Unlike surface antigens such as Spike (S), N is much less likely to mutate, providing a broader and more universal immune response, with the objective inducing broad-spectrum protection against all current and future variants of SARS-CoV-2 as well as against future pandemic coronavirus strains. Osivax’ oligoDOMTM technology enables the design and production of a recombinant version of the nucleocapsid which self-assembles into a nanoparticle, thus triggering powerful T- and B-cell immune responses. OVX033 has demonstrated a preclinical proof of concept for cross-protective efficacy in a hamster challenge model published in Frontiers in Immunology. Further preclinical studies and a First-In-Human clinical trial are ongoing. This project is supported by the French government, through France 2030, “Programme Investissements d’Avenir” operated by Bpifrance. About Osivax Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOMTM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide. For further information: View source version on businesswire.com: Contacts Alexandre LE VERT, CEO contact@osivax.com +33 (0)9 70 30 13 80 For Media Inquiries Trophic Communications Desmond James or Valeria Fisher osivax@trophic.eu +49 (0) 151 678 59086 or +49 (0) 175 804 1816 Source: Osivax View this news release online at:

LYON, France--(BUSINESS WIRE)-- Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer. She brings over 25 years of experience in vaccine development with considerable expertise in influenza vaccines, from early-stage clinical development to approval and post-marketing commitments. Dr. Groth joins Osivax as the company advances the development of its lead candidate, OVX836, a best-in-class broad-spectrum influenza vaccine candidate currently being evaluated in several Phase 2 clinical trials. Dr. Groth takes over from Dr. Willems, whose contribution has been instrumental in advancing Osivax’ clinical strategy. “We are thrilled to announce the addition of Nicola to our executive team as CMO. With her extensive leadership background in vaccine development and interactions with regulatory agencies, particularly in influenza vaccines, she brings invaluable expertise to our organization. Nicola’s experience in managing late-stage clinical trials and building registration packages for influenza vaccines will be crucial as we progress OVX836 through Phase 2 clinical testing and approach the clinic with our universal coronavirus vaccine candidate, OVX033,” commented Alexandre Le Vert, CEO and Co-Founder of Osivax. “I would also like to express my gratitude for the contributions of Dr. Paul Willems, MD, whose dedication has brought Osivax to this point of development.” “Joining the high-performing team at Osivax represents a unique opportunity to support the development of a new class of vaccines capable of providing broad-spectrum protection against infectious viruses and diseases that continue posing global health threats,” said Dr. Nicola Groth, CMO of Osivax. “I am eager to lend my expertise to further drive Osivax’ clinical programs and impact in this field.” Before joining Osivax, Dr. Groth served as Global Head of Safety Evaluation & Risk Management at GlaxoSmithKline (GSK) Vaccines. She has also held various strategic positions in vaccine development, epidemiology, and medical affairs at Novartis Vaccines and Diagnostics and the Chiron Corporation. Nicola Groth holds a Doctor of Medicine and a PhD in Hygiene and Preventive Medicine from the University of Siena, Italy. About Osivax Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide. For further information: View source version on businesswire.com: Contacts Alexandre Le Vert, CEO contact@osivax.com +33 (0)9 70 30 13 80 For Media Inquiries Trophic Communications Desmond James or Valeria Fisher osivax@trophic.eu +49 (0) 151 678 59086 or +49 (0) 175 804 1816 Source: Osivax View this news release online at: